Metformin delayed release - Elcelyx Therapeutics

Drug Profile

Metformin delayed release - Elcelyx Therapeutics

Alternative Names: EFB0027; Met DR; NewMet

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elcelyx Therapeutics
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 10 Nov 2016 Positive safety and efficacy results from a phase IIb trial in Type-2 diabetes mellitus released by Elcelyx Therapeutics
  • 01 Sep 2016 Elcelyx Therapeutics completes a phase IIb trial in Type-2 diabetes mellitus in USA and Puerto Rico (NCT02526524)
  • 25 May 2016 Elcelyx Therapeutics completes enrolment in its phase IIb trial for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top